Could a daily pill tame rare cancers in teens? new trial investigates

NCT ID NCT07700758

Not yet recruiting Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 2 trial tests the safety of belzutifan, a daily oral tablet, in adolescents with rare solid tumors that cannot be surgically removed or have spread. The study includes three tumor types: pheochromocytoma/paraganglioma (PPGL), wild-type gastrointestinal stromal tumors (wtGIST), and von Hippel-Lindau (VHL) disease-associated tumors. Researchers aim to see how many participants experience side effects and whether they can tolerate the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belzutifan, an oral tablet taken once daily
What this could lead to: If successful, this trial could show that belzutifan is a safe and tolerable treatment option for adolescents with certain rare solid tumors.
What could go wrong: This is an early-phase, small study (15 participants) focused on safety, not yet on how well the drug works. The results may not apply to all patients or tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer gastrointestinal stromal tumor neoplasm pheochromocytoma-paraganglioma von Hippel-Lindau disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM

More trials for these conditions

Other studies related to the condition(s) this trial covers.